Compare MetLife Inc. Common Stock (MET) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MetLife Inc. Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? MetLife Inc. Common Stock trades at $100.15 (market cap $63.96B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: MetLife Inc. Common Stock is far larger — about 65.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and MetLife Inc. Common Stock pays a 2.35% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MetLife Inc. Common Stock for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MET | MRVI | |
|---|---|---|
Market Cap | $63.96B | $972.90M |
Volume | 3,016,459 | 4,325,710 |
Sector | Financials | Health |
52-Week High | $100.65 | $9.00 |
52-Week Low | $67.70 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $84.89B | $1.08B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MetLife (MET) trades at $100.65, up 0.48% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with a P/E of 19.28 and a net income margin of 4.66%. Recent news highlights a declared dividend of $0.59 per share and upcoming Q3 2026 results.
The outlook for MET is positive, driven by earnings momentum and a favorable interest rate environment for insurers. Key risks include investment income volatility and competitive pressures. With a consensus price target of $108.25 and no sell ratings, Wall Street sentiment remains bullish, though the stock's RSI suggests potential near-term overbought conditions.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MetLife Inc. Common Stock
MetLife provides insurance, annuities, employee benefits, and asset management services. Its products serve individuals, employers, and institutions.
Read more on MET →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
